Clinical Trial VICCBMT1020


Impact of First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment with Velcade Based Therapy

Principal Investigator(s)

Madan Jagasia


  • Protocol No. VICCBMT1020
  • Open Date: 11/15/2010
  • Staging: Phase II
  • Age Group: Adults
  • Scope: Local
  • Objective: To show that HDC and ASCT significantly increases MRD negativity (as measured by 7 color flow cytometry) from 20% to 40% at 3 months post transplant.
  • Disease Sites: Bone Marrow Transplant
  • Therapies: Chemotherapy - cytotoxic
  • Drugs: Bortezomib (BTZ); Dexamethasone; Doxorubicin; Lenalidomide; PS-341 (VELCADE); VELCADE
  • Participating Institutions: Vanderbilt University; Boston Baskin Cancer Group (UTCI); Kansas University Medical Center
  • National Clinical Trial ID: NCT01215344
  • Secondary Protocol No: X05338



Learn More

You do not have JavaScript enabled. This site works better with JavaScript turned on.